Rapamycin Nanoparticles Extend Lifespan by 70% in C. elegans

Rapamycin has emerged as one of the most promising pharmacological candidates for extending healthy lifespan, operating primarily through inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway — a central regulator of cellular growth, autophagy, and aging. Despite decades of evidence supporting its longevity effects in model organisms and growing interest in human use, rapamycin's clinical translation is significantly constrained by its poor water solubility, chemical instability, and erratic oral bioavailability. Addressing these pharmacological limitations is therefore a meaningful step toward realizing rapamycin's longevity potential in human applications.

In this study, researchers from São Paulo State University and the University of Navarra developed and characterized rapamycin-loaded human serum albumin nanoparticles coated with polyethylene glycol (PEG). The nanoparticles were produced via desolvation, a standard protein nanoparticle fabrication method, and subsequently PEGylated to improve systemic stability. The resulting particles fell within the 150–200 nm size range optimal for intravenous delivery and passive tumor targeting, exhibited low polydispersity, a negative zeta potential of approximately -30 mV, and achieved encapsulation efficiency exceeding 70%.

Drug release followed a sustained biphasic profile — approximately 40% over 24 hours — well described by the Weibull mathematical model, suggesting controlled and predictable pharmacokinetics. In vitro testing in MCF-7 human breast cancer cells demonstrated cytotoxicity comparable to free rapamycin, but at lower IC50 concentrations, indicating enhanced potency per dose. The most compelling result came from C. elegans lifespan assays: nanoparticle-encapsulated rapamycin extended worm lifespan by approximately 70%, significantly outperforming free rapamycin, without altering fat content or inducing detectable carrier toxicity.

These findings suggest that improved drug delivery can substantially amplify rapamycin's biological effects beyond what the free compound achieves. For the longevity field, this is significant: if the platform enhances mTOR inhibition efficiency or improves tissue distribution in vivo, it could enable lower effective doses in mammals, potentially reducing immunosuppressive side effects that concern clinicians and self-experimenters alike.

Caveats include the preclinical nature of the data — C. elegans and cell lines are useful but limited proxies for mammalian aging — and the summary is based solely on the published abstract.